The Kv7 potassium channel activator retigabine decreases alcohol consumption in rats

References

• Weiss F, Porrino LJ. Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci 2002;22:3332–3337
   PubMed Web of Science ®Google Scholar
• Söderpalm B, Löf E, Ericson M. Mechanistic studies of ethanol’s interaction with the mesolimbic dopamine reward system. Pharmacopsychiatry 2009;42:S87–S94
   Web of Science ®Google Scholar
• Crosby SJ, Knapp CM, Kornetsky C. The effect of intraperitoneal ethanol administration on brain-stimulation reward in mice using a rate-independent pyschophysical method. Alc Clin Exp Res 2008;32:36A
   Google Scholar
• Fish EW, Riday TT, McGuigan MM, Faccidomo S, Hodge CW, Malanga CJ. Alcohol, cocaine, and brain stimulation-reward in C57Bl6/J and DBA2/J mice. Alcohol Clin Exp Res 2010;34:81–89
   Google Scholar
• Moolten M, Kornetsky C. Oral self-administration of ethanol and not experimenter-administered ethanol facilitates rewarding electrical brain stimulation. Alcohol 1990;7:221–225
   Google Scholar
• Knapp C, Kornetsky C. Neural basis of pleasure and reward. In: Bernston GG, Cacioppo JT, editors. Chapter 40. Handbook of neuroscience for the behavioral sciences. UK: John Wiley & Sons; 2009
   Google Scholar
• Imperato A, Di Chiara G. Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. J Pharmacol Exp Ther 1986;239:219–228
   PubMed Web of Science ®Google Scholar
• Ding ZM, Rodd ZA, Engleman EA, McBride WJ. Sensitization of ventral tegmental area dopamine neurons to the stimulating effects of ethanol. Alcohol Clin Exp Res 2009;33:1571–1581
   Google Scholar
• Brodie MS. Increased ethanol excitation of dopaminergic neurons of the ventral tegmental area after chronic ethanol treatment. Alcohol Clin Exp Res 2002;26:1024–1030
   PubMed Web of Science ®Google Scholar
• Brodie MS, Pesold C, Appel SB. Ethanol directly excites dopaminergic ventral tegmental area reward neurons. Alcohol Clin Exp Res 1999;23:1848–1852
   PubMed Web of Science ®Google Scholar
• Gessa GL, Muntoni F, Collu M, Vargiu L, Mereu G. Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res 1985;348:201–203
   PubMed Web of Science ®Google Scholar
• Hansen HH, Ebbesen C, Mathiesen C, Weikop P, Rønn LC, Waroux O, Scuvée-Moreau J, et al. The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat. J Pharmacol Exp Ther 2006;318:1006–1019
   Google Scholar
• Hansen HH, Waroux O, Seutin V, Jentsch TJ, Aznar S, Mikkelsen JD. Kv7 channels: interaction with dopaminergic and serotonergic neurotransmission in the CNS. J Physiol 2008;586:1823–1832
   Google Scholar
• Delmas P, Brown DA. Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nature Neurosci Rev 2005;6:850–862
   PubMed Web of Science ®Google Scholar
• Drion G, Bonjean M, Waroux O, Scuvée-Moreau J, Liégeois JF, Sejnowski TJ, Sepulchre R, Seutin V. M-type channels selectively control bursting in rat dopaminergic neurons. Eur J Neurosci 2010;31:827–835
   Google Scholar
• Moore SD, Madamba SG, Siggins GR. Ethanol diminishes a voltage-dependent K+ current, the M-current, in CA1 hippocampal pyramidal neurons in vitro. Brain Res 1990;516:222–228
   Google Scholar
• Koyama S, Brodie MS, Appel SB. Ethanol inhibition of m-current and ethanol-induced direct excitation of ventral tegmental area dopamine neurons. J Neurophysiol 2007;97:1977–1985
   Google Scholar
• Hansen HH, Andreasen JT, Weikop P, Mirza N, Scheel-Krüger J, Mikkelsen JD. The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine. Eur J Pharmacol 2007;570:77–88
   PubMedGoogle Scholar
• Sotty F, Damgaard T, Montezinho LP, Mørk A, Olsen CK, Bundgaard C, Husum H. Antipsychotic-like effect of retigabine [N-(2-Amino-4-(fluorobenzylamino)-phenyl)carbamic acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission. J Pharmacol Exp Ther 2009;328:951–962
   PubMedGoogle Scholar
• Jensen MM, Lange SC, Thomsen MS, Hansen HH, Mikkelsen JD. The pharmacological effect of positive KCNQ (Kv7) modulators on dopamine release from striatal slices. Basic Clinl Pharmacol Toxicol 2011;109:339–342
   Google Scholar
• Martire M, D’Amico M, Panza E, Miceli F, Viggiano D, Lavergata F, Iannotti FA, et al. Involvement of KCNQ2 subunits in [3H]dopamine release triggered by depolarization and pre-synaptic muscarinic receptor activation from rat striatal synaptosomes. J Neurochem 2007;102:179–193
   Google Scholar
• Stromberg MF, Casale M, Volpicelli L, Volpicelli JR, O’Brien CP. A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and beta-funaltrexamine on ethanol consumption in the rat. Alcohol 1998;15:281–289
   PubMed Web of Science ®Google Scholar
• Stromberg MF, Mackler SA, Volpicelli JR, O’Brien CP. Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption. Alcohol 2001;23:109–116
   Google Scholar
• Olive MF, Nannini MA, Ou CJ, Koenig HN, Hodge CW. Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release. Eur J Pharmacol 2002;15:55–61
   Web of Science ®Google Scholar
• Knapp CM, Mercado M, Markley TL, Crosby S, Ciraulo DA, Kornetsky C. Zonisamide decreases ethanol intake in rats and mice. Pharmacol Biochem Behav 2007;87:65–72
   PubMed Web of Science ®Google Scholar
• Knapp CM, Tozier L, Pak A, Ciraulo DA, Kornetsky C. Deep brain stimulation of the nucleus accumbens reduces ethanol consumption in rats. Pharmacol Biochem Behav 2009;92:474–479
   PubMed Web of Science ®Google Scholar
• Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007;10;298:1641–1651
   Google Scholar
• Arias AJ, Feinn R, Oncken C, Covault J, Kranzler HR. Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. J Clin Psychopharmacol 2010;30:318–322
   PubMed Web of Science ®Google Scholar
• Sarid-Segal O, Knapp CM, Burch W, Richardson MA, Bahtia S, DeQuattro K, Afshar M, et al. The anticonvulsant zonisamide reduces ethanol self-administration by risky drinkers. Am J Drug Alcohol Abuse 2009;35:316–319
   PubMed Web of Science ®Google Scholar
• Voges J, Müller U, Bogerts B, Münte T, Heinze HJ. Deep brain stimulation surgery for alcohol addiction. World Neurosurg 2013;80:S28.e21--S28.e3
   Google Scholar
• SAS version 9.1.3. SAS Institute Inc., Cary, NC, USA; 2002–2003
   Google Scholar
• Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia 2012;53:412–424
   PubMed Web of Science ®Google Scholar
• Rundfeldt C, Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 2000;50:1063–1070
   PubMed Web of Science ®Google Scholar
• Korsgaard MP, Hartz BP, Brown WD, Ahring PK, Strøbaek D, Mirza NR. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J Pharmacol Exper Ther 2005;314:282–292
   PubMedGoogle Scholar
• Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos EE, Kutscher B, et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 1996;23:211–223
   PubMed Web of Science ®Google Scholar
• Hopf FW, Simms JA, Chang SJ, Seif T, Bartlett SE, Bonci A. Chlorzoxazone, an SK-type potassium channel activator used in humans, reduces excessive alcohol intake in rats. Biol Psychiatry 2011;69:618–624
   PubMed Web of Science ®Google Scholar